High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. (Q38724794)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 December 2016

Language	Label	Description	Also known as
English	High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.	scientific article published on 22 December 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Jennifer E Hardingham

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

S S Kumar

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Y Tomita

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

M Bruhn

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

A Swalling

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

M Mohammed

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

T J Price

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

publication date

22 December 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

718-726

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Biomarkers in colorectal cancer: the future is getting closer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

MYC Is a Major Determinant of Mitotic Cell Fate

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Cell survival and metastasis regulation by Akt signaling in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Gastrin inhibits a novel, pathological colon cancer signaling pathway involving EGR1, AE2, and P-ERK.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

The epidermal growth factor receptor pathway: a model for targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

HER2 activating mutations are targets for colorectal cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

TNF-α promotes invasive growth through the MET signaling pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Consistency test of the cell cycle: roles for p53 and EGR1.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-016-1596-8

21 January 2018

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulatory mechanisms of the HB-EGF autocrine loop in inflammation, homeostasis, development and cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-016-1596-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28005260%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38724794&oldid=2202012578"